Exhaled nitric oxide and its relationship to airway responsiveness and atopy in asthma  by Lúdvíksdóttir, D. et al.
RESPIRATORY MEDICINE (1999) 93, 552-556 
Exhaled nitric oxide and its relationship to 
airway responsiveness and atopy in asthma 
D. L~~Dv~K~&TTIR*, C. JANSON *, M. H&MAN?, H. HEDENSTR~M~ E. BJBRNSSON* AND 
G. BOMAN* ON BEHALF OF THE BHR-STLJDY GROUP 
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Exhaled nitric oxide (NO) has attracted increasing interest as a non-invasive marker of airway inflammation. The 
purpose of this study was to determine whether exhaled nitric oxide in subjects with asthma varied according to 
their atopic status and to examine its correlation with airway hyperresponsiveness and lung function measurements. 
Forty patients with asthma and 13 controls participated in the study. Nitric oxide was measured on three 
occasions with intervals of at least 3 days, using a chemiluminescence method. Airway responsiveness was assessed 
with methacholine challenge and lung function measurements were made. All subjects recorded peak expiratory 
flow and kept a symptom diary during a 17-day period. There was no significant difference in lung function 
measurements, peak expiratory flow or symptom score between the two asthma groups. Atopic patients with 
asthma had a significantly higher mean amount of exhaled NO than non-atopic subjects with asthma (162 &- 68 VS. 
113*55 nl min-‘; P = 0.03) and the control group (88 + 52 nl min-‘; P = 0.004). No significant difference was 
found in the amount of exhaled NO between non-atopic patients with asthma and the controls. In atopic subjects 
with asthma the mean exhaled NO was significantly correlated to the dose-response slope for methacholine 
(r = -0.52; P=O*O2), while no such correlation was found in the non-atopic group. 
In conclusion; in this study, atopic subjects with asthma had higher levels of exhaled NO than non-atopic 
subjects. Atopic status should be taken into account when measuring levels of exhaled NO in subjects with asthma. 
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Introduction 
Exhaled nitric oxide (NO) is elevated in subjects with 
inflammatory pulmonary diseases (1) and has attracted 
The BHR study group: Anders Ahlander’, Kawa Amin5, Eyth6r 
Bjiirnsson’, Gunnar Bornan’, Britt-Marie Eriksson6, Bjiirn Gudb- 
j6rnsson3, Monika Hall’, Giiran Hedenstierna’, Hans Heden- 
stram’, Lena Hgkansson4, Marieann H6gman2, Christer Janson’, 
Maria Lampinen4, Kerstin Lindblad4, D&a Ltidviksdbttir’, Otto 
Nettelbladt’, Godfried Roomans’, Lahja %&IS’, Ulrike-Spetz- 
NystrGm’, Gunnemar Sdlenheim’, Sigridur Valtysdbttir3, Per 
Venge4, Charlotte Woschnagg4. 
Department of Respiratory Medicine and Allergology’, Department 
of Clinical Physiology2, Department of Rheumatology3. Department 
of Clinical Chemistry4, Department of Anatomys, Department of 
Infectious Disease?, Asthma Research Centre. Uppsala University, 
Sweden; Pharmacia & Upjohn Diagnostics AB, Uppsala, Sweden7. 
Received 24 Febraury 1999 and accepted in revised form 21 April 
1999. 
Correspondence should be addressed to: Dr. D6ra Lidviksdbttir, 
Department of Respiratory Medicine and Allergology Akademiska 
sjukhuset SE-751 85 Uppsala Sweden. Fax: +46 18662819. 
0954-6111/99/080552+05 $12.00/O 
increasing interest as a simple, non-invasive marker of 
airway inflammation. In asthma, exhaled NO levels are 
elevated (2,3) and increase following allergen challenge (4) 
and during asthmatic exacerbations (5). 
NO is synthesized by a group of three enzymes, called 
NO synthases (NOS), all of which have been detected in 
lung cells. There is evidence of the secretion of multiple 
cytokines in asthmatic airways, including tumour necrosis 
factor-a(TNF-a), interleukin-I p(IL-1 p) and interferon- 
gamma (IFN-?I) (6), which are known to increase the 
expression of the inducible NOS in the airway epithelial 
cells (7). The inducible NOS is markedly expressed in 
asthmatic airways (8), thereby explaining high levels of 
exhaled NO in asthma. 
To our knowledge, all previous studies of exhaled NO in 
adult patients with asthma have included only atopic 
subjects and little is known about exhaled NO levels in non- 
atopic patients with asthma. 
The purpose of this study was to determine whether 
exhaled nitric oxide in subjects with asthma varied 
according to their atopic status and to examine its 
correlation with airway hyperresponsiveness and lung 
function measurements. 
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Patients and methods 
SUBJECTS 
Fifty-three subjects aged 17-64 years, participated in the 
study. The clinical characteristics of the subjects are shown 
in Table 1. Patients with asthma were recruited from the 
Department of Respiratory Medicine and Allergology at 
our hospital. Subjects were defined as having asthma if they 
had asthma diagnosed by a physician (9). All of them had 
had respiratory symptoms during the past 12 months, a 
forced expiratory volume in 1 set (FEVi) above 70% of the 
predicted value and had previously demonstrated an 
increased responsiveness to inhaled methacholine (10). 
Patients with asthma who had at least one positive skin- 
prick test were defined as having atopy. Skin-prick tests 
were carried out using Solu Prick (ALK, Denmark) 
standardized allergen extract against the following aller- 
gens: birch, timothy grass, mugwort, cat, dog, horse, 
Dermatophagoides pteronyssinus, Cladosporium and Alter- 
naria. A positive test was a reaction with a mean size of 2 3 
mm and no dermatographism. 
Fourteen (70%) of the atopic patients with asthma and 
15 (75%) of the non-atopic patients with asthma were 
receiving regular treatment with inhaled glucocorticoids 
[budesonide (n = 25) or beclomethasone (n = 4)]. There was 
no statistical difference in steroid treatment between the 
two groups. The mean daily dose of inhaled steroids was 
447 pg in the atopic asthma group (n = 13) and 667 pg in the 
non-atopic asthma group (n = 13). Data on doses of inhaled 
steroids were missing in one atopic patient with asthma and 
in two non-atopic patients with asthma. Inhaled corticos- 
teroid therapy was continued with no changes. All the 
patients but one with asthma were taking inhaled /?z- 
agonists as required. None of the patients was being treated 
with theophylline compounds. One atopic subject with 
asthma and eight non-atopic patients with asthma were ex- 
smokers (stopped smoking 2-20 years previously). 
The control group comprised 13 subjects who responded 
to a request for volunteers or were recruited from the staff 
at our hospital; none had asthmatic symptoms or was on 
anti-asthmatic treatment and all were non-atopic (Table 1). 
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All the investigated subjects were non-smokers and had 
been free from respiratory infections for at least 6 weeks 
prior to the study and none had a history of cardiovascular 
disease. All the participants received a questionnaire on the 
occurrence of airway symptoms in the past 12 months. The 
questionnaire was based on the European Community 
Respiratory Health Survey questionnaire (11). The study 
was conducted in accordance with the Declaration of 
Helsinki and was approved by the Ethics Committee at the 
Medical Faculty at Uppsala University. Verbal informed 
consent was obtained prior to the study. 
STUDY DESIGN 
Peak flow and symptom diaries were kept during a 17-day 
period, starting on the day of inclusion in the study. Nitric 
oxide was measured on three occasions at least 3 days apart 
and within 3 weeks in each individual. At these visits, 
bronchial challenges and lung function measurements were 
made. Bronchial challenges were performed after the NO 
measurements. 
NITRIC OXIDE MEASUREMENTS 
Nitric oxide in mixed expired gas was measured over a 5- 
min period using a chemiluminescence NO analyser (model 
42, Therm0 Environmental Instruments Inc., Franklin, 
MA, USA). The system was calibrated with a mixture of 
NO in N2 (AGA Gas AB, Lidingo, Sweden) with a 
concentration of 1 ppm. A four-point calibration was thus 
performed (0,10,100,1000 ppb). The calibration of the 
system was tested every morning and zero was set before 
each patient. The patient, with a nose clip in place, was 
connected to a three-way valve (Hans Rudolph, Inc., 
Kansas City, MO, USA) by a mouthpiece and inhaled 
synthetic NO-free air (AGA Gas AB) from a reservoir and 
exhaled into a mixing box. The volume of the mixing box 
was l-5 1 and the box was made of stainless steel. This 
material is known not to influence NO measurements. NO 
samples were continuously drawn into the NO analyser 
from the mixing box. The exhaled volume was measured by 
TABLE 1. Characteristics of subjects with asthma and healthy controls as mean (range) 
Atopic subjects with asthma Non-atopic subjects with asthma Controls 
(n = 20) (n = 20) (n= 13) 
Age (years) 
Gender (M/F) 
Disease duration (years) 
Inhaled steroids 
FVC (% pred) 
FEVi (% pred) 
SGAW (% pred) 
Symptom score 
PEF variability (%) 
34 (18-63) 40 (17-64) 30 (22-52) 
9/11 l/19 419 
13 (0.3-29) 8 (0.542) 
14 15 
97 (74-138) 90 (71-110) 95 (77-106) 
93 (71-124) 88 (73-115) 95 (70-115) 
68 (21-122) 78 (38-160) 102 (59-223) 
2.4 (O-4) l-9 (O-4) 0 
7 (3-16) 8 (3-14) 5 (31-9) 
554 D. LtJ!WkStiTIR ETAL. 
a Wright spirometer. The amount of NO was calculated by 
multiplying the exhaled minute volume by the concentra- 
tion of NO in the exhaled gas and then expressing it in nl 
min-‘. NO values from the first minute were discharged 
and a mean value for each of the following minutes was 
obtained. 
SPIROMETRY 
Functional residual capacity (FRC), vital capacity (VC), 
airway resistance (RAW), specific airway conductance 
(SGAW), forced vital capacity (FVC) and forced expiratory 
volume in 1 set (FEVi) were measured after each challenge 
with a Masterlab Trans spirometer and a Masterlab body 
plethysmograph (Eric Jaeger AG, Wtirzberg, Germany). 
FVC, FEVi and SGAW were used for the study. Lung 
function values are presented as a percentage of reference 
values (12,13) 
METHACHOLINE CHALLENGES 
We used an automatic, inhalation-synchronized dosimeter 
jet nebuliser, Spira Elektro 2 (Respiratory Care Centre, 
Hameenlinna, Finland) (14). The bronchial challenges were 
performed from 0830 to 1100 hours. The subjects were 
instructed not to take any bronchodilatory drug 8 h prior to 
a test. Increasing doses of methacholine chloride (National 
Corporation of Swedish Pharmacies) in a 0.9% saline 
were given until a decrease in FEVi of 20% or the 
highest concentration was reached. Methacholine was 
inhaled during five breaths and lung function measurements 
followed in the next 3 min. Baseline values were obtained 
after an inhalation of saline. The methacholine was given in 
10 successively increasing doses ranging from 0.0625 mg 
ml-’ to 32 mg ml-‘. Patients with a provocative 
concentration (PC& of methacholine of 532 mg ml-’ 
and a decrease in FEVi of 20% or more were diagnosed as 
having a positive test. 
DOSE-RESPONSE SLOPE 
A least-squares slope for methacholine was calculated from 
the regression equation for the percentage decline in FEVi 
on a cumulative dose of methacholine using all the 
measured points (15). 
PEAK FLOW AND SYMPTOM DIARIES 
Peak flow and symptom diaries were kept during a 17-day 
period, starting on the day of inclusion in the study. The 
peak expiratory flow rate (best of three measurements) was 
recorded four times daily with a Mini-Wright peak flow 
meter (Clement Clarke, London, U.K.). Daily peak flow 
variability was calculated using the formula: highest PEF 
- lowest PEF x loo/mean PEF value of the day. On 
awakening, the subjects filled in the symptom diary and 
stated whether or not they had had: breathing difficulties 
the previous night, wheezing in the chest, attacks of 
breathlessness or attacks of coughing during the previous 
24 h. A symptom score (t&4) was calculated for each 
individual using the number of respiratory symptoms 
during the 17-day period. 
Statistics 
Comparisons between two groups were performed using the 
Mann-Whitney U-test. In correlations within a group, the 
Spearman Rank correlation test was used. ANOVA for 
repeated measurements was used to analyse whether there 
were any significant individual differences in the amount of 
exhaled NO between the three measurements. All the 
results are given as the mean + SD. A P-value of < 0.05 was 
regarded as statistically significant. 
Results 
LUNG FUNCTION, PEAK EXI’IRATORY 
FLOW AND SYMPTOM SCORE 
There was no significant difference in lung function 
measurements, peak expiratory flow or symptom score 
between atopic and non-atopic subjects with asthma 
(Table 1). 
No correlation was found between the amount of exhaled 
NO and lung function values, peak expiratory flow or 
symptom score in the two asthma groups or the controls. 
EXHALED NO IN PATIENTS WITH 
ASTHMA AND CONTROLS 
Atopic patients with asthma had a significantly higher 
mean amount of exhaled NO than non-atopic subjects with 
asthma (162+68 vs. 113+55 nl min-‘; P=O.O3) and the 
control group (88 f 52 nl min- ‘; P= 0.004) (Fig. 1). No 
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FIG. 1. Exhaled NO levels in atopic and non-atopic 
subjects with asthma and controls (0, subjects without 
airway hyperresponsiveness, 0, subjects with airway 
hyperresponsiveness). 
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significant difference was found in the amount of exhaled 
NO between non-atopic patients with asthma and the 
control group. There was no significant difference within 
the subjects between the three different NO measurements. 
The mean range of the NO measurements within subjects 
was 43 & 31 nl mm’. 
No significant correlation was found between the daily 
dose of inhaled steroids and levels of exhaled NO in either 
group of subjects with asthma. 
EXHALED NO AND AIRWAY 
HYPERRESPONSIVENESS 
Fifteen (75%) of the 20 atopic subjects with asthma, 12 
(60%) of the non-atopic subjects with asthma and two 
(15%) of the controls had a positive methacholine challenge 
(a fall in FEVi by 20% of the predicted value or more). 
There was no significant difference in dose response slope 
(DRS) for methacholine between atopic and non-atopic 
subjects with asthma. 
In atopic subjects with asthma the mean exhaled NO was 
significantly correlated to the dose-response slope for 
methacholine (r= -0.52; P=O*O2), while no such correla- 
tion was found in the non-atopic group. 
Discussion 
We found that atopic subjects with asthma had higher 
exhaled NO than non-atopic subjects with asthma, while no 
difference was found between the two groups in terms of 
lung function, peak expiratory flow and symptom score. 
Non-atopic subjects with asthma in this study had exhaled 
NO levels which were not significantly different from those 
of the controls. Furthermore, in atopic subjects with 
asthma, exhaled NO was significantly correlated to the 
dose-response slope for methacholine, while no such 
correlation was found in the other two groups. 
To our knowledge, this is the first study to demonstrate 
differences in the amount of exhaled NO in an atopic and 
non-atopic adult population with asthma. 
Our results correspond to those recently reported by 
Frank et al. showing higher exhaled NO levels in atopic 
asthmatic children than non-atopic asthmatic children, 
regardless of whether or not they were receiving inhaled 
corticosteroids (16). Atopy therefore appears to be an 
important determinant of the amount of exhaled NO in 
asthma. In a study of healthy children, exhaled nitric oxide 
increased in children with a positive skin-prick test and 
increased as the number of positive skin-prick tests increased 
(17). In infants, the levels of exhaled nitric oxide are higher in 
those with a family history of atopy (18). Even atopic, non- 
asthmatic adults with seasonal rhinitis have displayed 
increased levels of both nasally and orally measured nitric 
oxide (19), indicating that atopic status independent of the 
asthma diagnosis may be an important determinant of 
increased nitric oxide production in the airways. 
How can atopic status determine nitric oxide production 
in patients with asthma? Exhaled NO increases during the 
late response to allergen (4), suggesting that allergen 
induces an increase in iNOS expression in the airways. 
The mechanism for the late response is not completly 
understood, but it involves the release of several intlam- 
matory mediators and cytokines. IL- 1 B, TNF-cx and IFN-y 
can all increase iNOS expression and NO formation in 
airway epithelial cells (7,8). Human mast cells are among 
the most active cells when it comes to generating pleiotropic 
cytokines including TNF-42O), which might explain the 
increase in NO in atopic subjects with asthma. Further- 
more, the mast cells of atopic subjects are in an activated 
state and may therefore be capable of releasing mediators 
more easily than the mast cells of non-atopic subjects. 
However, it should be recognized that the majority of 
both atopic and non-atopic subjects with asthma were 
receiving treatment with inhaled corticosteroids, which can 
affect exhaled nitric oxide levels (21) and further studies of 
asthmatics who have not yet started inhaled steroid therapy 
are needed. This study was designed and performed before 
the guidelines for NO were published (22). A disadvantage 
with our method is the risk of mixing of NO from the nose. 
To limit this problem our measurements were made during 
exhalation with a nose clip. In this way, nasal NO will give 
little contribution to the exhaled gas concentration. This is 
supported by the fact that the NO values in our control 
group were of the same level as the NO values of the 
healthy subjects in the study reported by Hiigman et al (23). 
Our data appear to be consistent with the findings of 
Jatakanon et al., who found a correlation between exhaled 
NO and airway hyperresponsiveness to methacholine (24). 
The correlation between exhaled NO and the dose-response 
slope for methacholine in atopic subjects with asthma in 
this study suggests that elevated NO levels or the 
mechanism leading to its increase may contribute to airway 
hyperresponsiveness. 
In conclusion, in this study, atopic subjects with asthma 
had higher levels of exhaled NO than non-atopic subjects. 
Atopic status should be taken into account when measuring 
levels of exhaled NO in subjects with asthma. 
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